CLINICAL_TRIALS ClinicalTrials.gov record update

PembroLizumab Adjuvant in Patients With Early-stage Triple NEgaTive Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy - the Multicenter, Randomized Phase III, Pragmatic PLANET Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07486687
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:11.078034+00:00
Published At: 2026-03-20T00:00:00+00:00
Record Updated At: 2026-03-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Triple Negative Breast Cancer (TNBC), Early Setting", "Early Stage Triple-Negative Breast Carcinoma", "Triple -Negative Breast Cancer", "Breast Cancer Stage II", "Breast Cancer Stage III"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-20"
protocolSection.identificationModule.nctId: "NCT07486687"
protocolSection.identificationModule.officialTitle: "PembroLizumab Adjuvant in Patients With Early-stage Triple NEgaTive Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy - the Multicenter, Randomized Phase III, Pragmatic PLANET Trial"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.